Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis

By Xianlin Han, David M Holtzman, Daniel W. McKeel, John Kelley, John C. Morris. Journal of Neurochemistry, 2002

609 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. (2003, methodology): “regions from AD subjects with very mild dementia (45).”
Metabolomics: a global biochemical approach to drug response and disease. (2008, background): “Initial metabolomic signatures have already been reported for several disease states, including motor neuron disease (19), depression (20), schizophrenia (21–23), Alzheimer’s disease (24), cardiovascular and coronary artery”
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. (2004, background): “Widespread and diffuse myelin breakdown has been reported to occur in AD subjects despite the lack of evidence of infarction, Wallerian degeneration, or white matter amyloid angiopathy [15,18,31,34,58,59,72,196] and these white matter deficits are observed at the earliest or preclinical stages of th”